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symptoms, the duration of symptoms, impact on social life, 
and patient complaints. The physicians treating thyroid can-
cer patients also responded to the survey and provided their 
perceptions of patient symptoms and treatment decisions. 
 Results: About 70% of the patients responded that they ex-
perienced a negative physical or psychological impact on 
their life and work due to hypothyroid symptoms. However, 
76% of doctors thought hypothyroidism could negatively 
impact a patient’s daily life but would be endurable. Two 
thirds of physicians do not routinely recommend recombi-
nant human TSH (rhTSH) to their patients. Multivariate anal-
ysis showed patients with female sex, stronger educational 
background, emotionally negative experiences of hypothy-
roidism, and younger age were more willing to pay for ther-
apy that could prevent hypothyroidism symptoms.  Conclu-
sions: There was a substantial gap in the perception of hy-
pothyroid symptoms during THW between physicians and 
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 Abstract 
 Background: Acute short-term hypothyroidism induced by 
thyroid hormone withdrawal (THW) for follow-up surveil-
lance or therapeutic radioiodine causes patients with differ-
entiated thyroid cancer to suffer from a myriad of deleteri-
ous symptoms.  Objectives: To know how patient recogni-
tion of hypothyroid symptoms compares to physician 
perception of patient symptoms.  Methods: The survey was 
performed in 10 referral hospitals throughout Korea from 
December 2010 to May 2011 and targeted patients with to-
tal thyroidectomy and remnant ablation. The survey consist-
ed of questions regarding the effect of THW on patient 
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patients. Physicians who are aware of the seriousness of hy-
pothyroidism in their patients were more likely to recom-
mend the use of rhTSH for their patients. 
© 2015 European Thyroid Association
 Published by S. Karger AG, Basel
 Introduction 
 For the last 10 years, cases of thyroid cancer have dras-
tically increased, becoming the number one cancer in an-
nual incidence among Korean women in 2008  [1] . In the 
management of differentiated thyroid cancer (DTC), thy-
roid hormone withdrawal (THW) has been an essential 
part of the diagnostic process and treatment to elevate 
TSH levels using radioactive iodine. However, acute 
short-term hypothyroidism induced by THW is the most 
distressing time during follow-up for DTC patients and 
can result in a myriad of deleterious symptoms and im-
paired quality of life (QoL)  [2, 3] .
 According to the recent clinical practice guidelines, re-
combinant human TSH (rhTSH) can be used as an alterna-
tive to THW for remnant ablation or for surveillance of can-
cer recurrence during the follow-up period in DTC patients 
 [4, 5] . However, in many Asian countries including Korea, 
using rhTSH in those situations is restricted mainly due to 
its high costs and reimbursement issues  [6] . Given the re-
strictions surrounding the use of rhTSH, if physicians had a 
better awareness of potential patient discomfort induced by 
THW, they might be more inclined to prescribe this medica-
tion. However, there have been no studies evaluating patient 
or physician awareness of acute hypothyroid symptoms 
during THW in an Asian country. In particular, physician 
perception of patient symptoms could affect the decision to 
treat and the disease outcome. Evaluation of the differences 
between physician and patient perceptions of symptoms in-
duced by the disease itself or during treatment is a very im-
portant step in the management of symptoms  [7] .
 The aim of this study was to evaluate the effect of THW 
for radioiodine therapy or follow-up testing on patient 
QoL and to determine if there is any difference in the per-
ception of acute hypothyroid symptoms between patients 
and their doctors.
 Patients and Methods 
 Study Subjects 
 This survey was prospectively performed in 10 tertiary referral 
hospitals throughout Korea from December 2010 to May 2011. 
All enrolled patients underwent total thyroidectomy with or with-
out lymph node dissection and remnant ablation as needed. The 
patients who had undergone a diagnostic whole body scan (WBS) 
or radioiodine therapy with THW within the previous 6 months 
were enrolled in this survey so as to maximize patient ability to 
recall their symptoms during THW. A total of 700 patients re-
sponded to the survey questionnaire in an outpatient setting. The 
survey questions are provided in the online supplementary ques-
tionnaires (for online suppl. material, see www.karger.com/
doi/10.1159/000371512).
 During the same period, a doctor questionnaire (DQ) was sent 
via e-mail to 35 physicians treating DTC patients from 20 tertiary 
hospitals, and they were asked to complete the questionnaire. A 
total of 35 physicians, composed of 31 endocrinologists, 2 nuclear 
physicians, and 2 endocrinologist-nuclear physicians, completed 
the questionnaire.
 This study was approved by the institutional review board of 
each participating hospital. Written informed consent was ob-
tained from all patients.
 Statistical Analysis 
 All data are expressed as number and proportion. A χ 2 test or 
Fisher’s exact test was used to compare differences between phys-
ical and mental disturbances in men and women. A multivariate 
logistic regression analysis was used to identify clinical or social 
factors for the decision as to pay the extra financial costs for avoid-
ing hypothyroidism. p < 0.05 was considered statistically signifi-
cant. SPSS 13.0 for Windows (SPSS Inc., Chicago, Ill., USA) soft-
ware was used for data analysis.
 Results 
 Among the 700 eligible patients who participated in 
the present survey, 532 patients (76.0%) responded to all 
of the questions and were included in the analysis. The 
baseline demographics of the study population are pre-
sented in the online supplementary table. 
 The most frequent patient symptom was fatigue, fol-
lowed by edema, difficulty in concentration, weight gain, 
depression, and nausea (in that order; Q6;  fig. 1 ). How-
ever, symptoms reported to physicians were fatigue and 
weight gain, followed by edema, joint/muscle pain, and 
constipation (DQ2;  fig. 1 ). 
 148 patients out of 253 (58.5%) experienced these 
symptoms for more than 3 weeks, even after resuming 
thyroid hormone replacement (Q7;  table 1 ). Female pa-
tients showed a more delayed recovery than males. 
Around 70% of patients indicated that the hypothyroid 
symptoms had a negative impact on daily life, both phys-
ically and emotionally, during the discontinuation of thy-
roid hormone ( table 2 ; Q8, Q9, and Q10). On the other 
hand, nearly all physicians expected their patients to ex-
perience physical (100.0%) and emotional (97.1%) distur-
bances ( table 2 ; DQ4 and DQ5). No gender differences 
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 Table 1.  Duration of hypothyroid symptoms during THW and resumption of thyroid hormone (Q7)
Respondents (n = 253)a  Duration of hypothyroid symptoms p
<2 weeks 2–4 weeks >4 weeks
Patients, n (%) 105 (41.5) 80 (31.6) 68 (26.9)
Age, years 45.8±11.4 48.6±11.1 49.2±10.1 0.086
Gender (female/total patients), n (%) 69/105 (65.7) 65/80 (81.2) 63/68 (92.6) 0.000
 a These patients described the exact duration of hypothyroid symptoms in the questionnaire (4.5 ± 5.6 weeks, range: 1–30).
 Table 2.  The differences between patient response and physician perception about physical discomfort (Q8/DQ4) and emotional and 
psychological impacts (Q9/DQ5) induced by THW
Questions Response Patients (n = 532) Doctors (n = 35) p
Physical discomfort (Q8/DQ4) no 150 (28.2) 0 (0) 0.001
somewhat 286 (53.8) 24 (68.6)
strong 96 (18.0) 11 (31.4)
Emotional and psychological no 171 (32.1) 1 (2.9) 0.001
impacts (Q9/DQ5) somewhat 285 (53.6) 26 (74.3)
strong 76 (14.3) 8 (22.9)
Male (n = 113) Female (n = 419)
Physical discomfort (Q8)  73 (64.6) 309 (73.8) 0.055
Emotional and psychological impacts (Q9) 65 (57.5) 296 (70.6) 0.008
 Values represent n (%). The differences according to the sex were shown in this table.
 Fig. 1. Symptoms experienced by patients 
during thyroid hormone discontinuation 
(Q6, multiple choices selected, gray bar) 
and doctors’ report of patient complaints 
during thyroid hormone discontinuation 
(DQ2, multiple choices selected, black bar). 
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were observed in terms of experiencing physical discom-
fort ( table  2 ), but more female patients suffered from 
emotional or psychological disturbance due to THW 
than did male patients.
 Table 3 shows how adequately doctors explained up-
coming hypothyroid symptoms and the prevention and 
alleviation of symptoms to their patients.
 Doctors believe that their patients’ experience of hypo-
thyroid symptoms could negatively impact patients’ daily 
life but that these symptoms are endurable, and two thirds 
of the doctors would not routinely recommend rhTSH 
( table 4 ). Patients prefer to have an alternative to THW to 
avoid suffering from hypothyroidism ( table 5 ). The more 
severe the patient symptoms were, whether physical or 
emotional, the more patients preferred rhTSH as an alter-
native method to THW (Q7, Q8, and Q14; p = 0.002 and 
p = 0.000, respectively)
 Multivariate logistic regression analysis showed that 
female sex, stronger educational background, emotion-
ally negative experiences of hypothyroidism, and young-
er age were significant variables associated with the deci-
sion to incur extra financial costs for avoiding hypothy-
roid symptoms if a method was available ( table 6 ).
 Table 3.  Doctor explanations to patients about upcoming hypothyroid symptoms and the prevention and alleviation of symptoms
 Response p
No Yes, but
somewhat
Yes, fully
Questions to patients (n = 530)
Q11 An explanation about the symptoms by the medical staff before the 
discontinuation of hormone 26 (4.9%) 175 (33.0%) 329 (62.1%) 0.081a
Q12 A full explanation about how to prevent and alleviate the 
symptoms by the medical staff before discontinuation 95 (17.9%) 175 (33.0%) 260 (49.1%) 0.404b
Q13 Separate treatment to control the symptoms (e.g. over-the-counter 
drugs or visit to an herbal doctor) 491 (92.6%) 39 (7.4%)
Questions to physicians (n = 35)
DQ7 Actually complaining their symptoms to physicians 1 (2.9%) 23 (65.7%) 11 (31.4%)
DQ8 Explaining to patients the symptoms which may occur and how to 
manage them 4 (11.4%) 15 (42.9%) 16 (45.7%)
 Values represent n (%). 
a The difference between Q11 and DQ8 was compared using a χ2 test.
b The difference between Q12 and DQ8 was compared using a χ2 test.
 Table 4.  Doctor response to question DQ9 and DQ10
Questions and answers n (%)
DQ9 What do you believe about the patient experience of hypothyroidism?
(1)  Most of patients will not experience hypothyroidism 0
(2) It will be a little tough but tolerable 20 (57.1)
(3) It will be a difficult and painful experience 15 (42.9)
(4) I don’t know 0
DQ10 Do you think Thyrogen treatment, which may replace the discontinuation of thyroid hormone, can be helpful to patients?
(1) I think it is helpful and actively recommend it 1 (2.9)
(2) It is helpful, but I recommend it only to some patients under specific conditions 22 (62.9)
(3) I give patients two options (discontinuation of hormone or Thyrogen) and let him/her make a decision 12 (34.3) 
(4) I think it is enough to discontinue thyroid hormone 0
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 Discussion 
 Acute short-term hypothyroid symptoms during 
THW for diagnostic WBS or radioiodine therapy are very 
debilitating and hamper the QoL of patients with DTC 
 [8–11] . Moreover, socioeconomic burdens including sick 
leave from work, as well as physical suffering, are mark-
edly increased in all patients undergoing this procedure 
for thyroid cancer management  [12] . To make things 
worse, some patients experiencing acute short-term hy-
pothyroid symptoms after THW also experience major 
psychiatric derangements, such as depression or anxiety, 
and the severity of the disease is comparable to that of 
patients with major depression requiring regular treat-
ment  [11, 13] .
 As considerable time may be needed for thyroid hor-
mone to fully act on transcription and translation of tar-
get proteins due to the long half-life of levothyroxine, 
many patients complain of hypothyroid symptoms sev-
eral weeks after the reinitiation of the thyroid hormone. 
Consistent with our results, one previous study showed 
that the impact of hypothyroidism on sick leave was much 
higher after, as compared to before, diagnostic WBS, sug-
gesting acute short-term hypothyroid symptoms may be 
more severe after the readministration of thyroid hor-
mones  [12] . Some patients did not recognize that delayed 
but still noticeable hypothyroid symptoms such as fa-
tigue, edema, and constipation might be attributable to 
THW because they did not understand the delayed action 
of thyroid hormone. Therefore, many patients may fre-
quently mistake that other causes such as radioiodine, not 
hypothyroidism due to THW, might have contributed to 
their symptoms. This is one reason why patients with thy-
roid cancer should be informed of their symptoms during 
and after preparation by THW. It is also why physicians 
should provide sufficient information and education to 
their patients.
 rhTSH, a recently developed synthetic human thyro-
tropin, has become a reliable alternative to THW for ini-
tial remnant ablation after total thyroidectomy or sur-
veillance with TSH-stimulated thyroglobulin or diagnos-
tic WBS  [4, 14] . Even though it has shown good efficacy 
for surveillance or remnant ablation in many previous 
studies, its wider use has been limited, especially in Asia, 
due to relatively high costs and potential lack of recogni-
tion of patients’ complaints by physicians during THW 
 [6] . 
 Our study showed a substantial gap in the level of 
perception of the severity of acute hypothyroid symp-
toms between physicians and patients during THW. 
 Table 5.  Patient response (respondents n = 532) to an alternative way to discontinuing thyroid hormone without 
suffering hypothyroidism (Q14)
 Response
co nsider it regardless 
of expense
consider it if it costs a
maximum of USD 1,000 
not consider 
it at all
Patients, n (%) 180 (33.8) 194 (36.5) 158 (29.7)
 Table 6.  Multivariate logistic regression analysis of influencing clinical parameters associated with willingness to 
incur additional financial costs to avoid hypothyroidism
Crude OR 95% CI Adjusted OR 95% CI
Age 0.96 0.95–0.98 0.98 0.96–0.99
Sex (vs. men) 1.40 0.90–2.17 1.90 1.11–3.26
Having a job 1.50 1.02–2.22 1.60 0.99–2.59
Stronger educational background 2.18 1.48–3.20 1.74 1.13–2.67
Experiences of physical discomfort 2.10 1.41–3.13 1.32 0.80–2.18
Experiences of emotional discomfort 2.15 1.46–3.17 1.71 1.05–2.78
OR = Odds ratio; CI = confidence interval.
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Usually, doctors have specific knowledge about hypo-
thyroid symptoms and their effects on the body. How-
ever, they might not have sufficient recognition regard-
ing the severity of acute hypothyroidism experienced by 
their patients ( table 4 ). In contrast to this, a more vague 
overestimation of patients’ symptoms by physicians ( ta-
ble 2 ) was detected from our data, which, however, did 
not seem to be connected to proper management. On 
the other hand, one previous report which evaluated 
QoL in patients with metastatic breast and prostate can-
cer showed that treating physicians usually underesti-
mate patient symptoms, while patients occasionally rat-
ed their symptoms as moderate to severe  [15] . This dis-
cordance may have an influence on the treatment 
decision of physicians and could discourage the fre-
quent use of rhTSH in patients with DTC, even though 
the physicians understand the ability of rhTSH to avoid 
hypothyroid symptoms, in addition to its diagnostic and 
therapeutic efficacy. 
 Around 7% of patients took over-the-counter medica-
tion, visited other doctors, or engaged in physical therapy 
in order to control their various hypothyroidism symp-
toms, although this supplemental treatment was not re-
ported to the physician ( table 3 ). While most patients re-
ceived sufficient information from their physicians about 
hypothyroid symptoms caused by THW, some did not 
actively consult their physicians about dealing with their 
symptoms. It is possible that patients regarded their 
symptoms induced by THW as an unavoidable, ‘must-
experience’ process to overcome during treatment or di-
agnosis, without considering alternative treatment meth-
ods, such as rhTSH. We could not posit detailed reasons 
for such responses from our survey alone. However, this 
patient belief reflects a greater gap between physicians 
and patients regarding management of acute hypothy-
roid symptoms. A more detailed understanding of the re-
lationship based on mutual understanding between phy-
sicians and patients is necessary to effectively address pa-
tient symptoms.
 Younger patients and those with a higher education 
had a tendency to seek alternatives for alleviating their 
hypothyroidism. This may be due to a better under-
standing of acute hypothyroid symptoms and alterna-
tive treatments, such as rhTSH injection. More strati-
fied, systematic, and educational approaches for vulner-
able patients would be needed to lessen their acute 
hypothyroid symptoms.
 To our knowledge, this is the first report that demon-
strates the considerable gap between patients and physi-
cians in recognition of acute hypothyroid symptoms dur-
ing preparation for diagnostic or therapeutic process with 
THW. Many physicians in Korea, even if they sufficient-
ly understood the hypothyroid symptoms of their pa-
tients, rarely suggested or provided to their patients the 
proper ways to relieve their symptoms, i.e. all perceptions 
of morbidity related to severe hypothyroidism did not 
lead to use of rhTSH. Some physicians might feel pressure 
to not use a high-cost alternative way compared to inex-
pensive conventional THW. Others might feel a relief 
that acute hypothyroid symptoms caused by THW could 
be endurable to their patients in the middle of thyroid 
cancer therapy. Passive use of alternative ways could be 
overcome by active communication between the treating 
physicians and patients, and by providing both with more 
accurate information about THW and its therapeutic 
 alternatives. 
 The present study has some limitations. First, there 
might be a selection bias due to the fact that only 532 
actively responding patients (76.0%) out of 700 respon-
dents were evaluated and data of the remaining 24.0% 
were dropped from our analysis, due to incomplete-
ness. This could bias the results toward those patients 
with more aggravated symptoms. Second, previously 
validated questionnaires for survey of health-related 
QoL such as the health survey short-form (SF-36) were 
not used in this study, which may limit the generaliz-
ability of patient symptoms and complaints to those 
with thyroid cancer. The patients should have been 
asked to grade each symptom, at least, with a visual an-
alogue scale. Third, we could not differentiate discom-
fort caused by iodine restriction from discomfort caused 
by acute hypothyroidism during THW. Generally, a 
low iodine diet might have caused additional discom-
fort in enduring the hypothyroid symptoms. Lastly, the 
majority of physicians who participated in the survey 
were endocrinologists and hence the results of the sur-
vey may not reflect the perception of physicians from 
other specialties (i.e. nuclear physicians, endocrine sur-
geons) on THW.
 In conclusion, many patients with DTC suffer from 
acute short-term hypothyroid symptoms induced by 
THW. Treating physicians should more actively consider 
an alternative way to decrease these symptoms in vulner-
able patients, such as using rhTSH.
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